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Protein stability and interactionsMethyl-CpG binding protein 2 (MeCP2) is a transcriptional regulator and a chromatin-associated structural pro-
tein. MeCP2 deregulation results in two neurodevelopmental disorders: MeCP2 dysfunction is associated with
Rett syndrome, while excess of activity is associatedwithMeCP2 duplication syndrome.MeCP2 is an intrinsically
disordered protein (IDP) constituted by six structural domains with variable, small percentage of well-defined
secondary structure. Two domains, methyl-CpG binding domain (MBD) and transcription repressor domain
(TRD), are the elements responsible for dsDNA binding ability and recruitment of the gene transcription/silenc-
ingmachinery, respectively. Previouslywe studied the influence of the completely disordered, MBD-flanking do-
mains (N-terminal domain, NTD, and intervening domain, ID) on the structural and functional features of the
MBD (Claveria-Gimeno, R. et al. Sci Rep. 2017, 7, 41,635). Here we report the biophysical study of the influence
of the remaining domains (transcriptional repressor domain, TRD, and C-terminal domains, CTDα and CTDβ)
on the structural stability ofMBD and the dsDNA binding capabilities of MBD and ID. The influence of distant dis-
ordered domains onMBD propertiesmakes it necessary to consider theNTD-MBD-ID variant as theminimal pro-
tein construct for studying dsDNA/chromatin binding properties, while the full-length protein should be
considered for transcriptional regulation studies.
© 2021 Published by Elsevier B.V.1. Introduction
Methyl-CpGbinding protein 2 (MeCP2) is a transcriptional regulator
involved in early stages of neuronal development, differentiation, mat-
uration, and synaptic plasticity control [1]. Besides this promoter-
specific dsDNA interaction required for finely tuning gene transcription,
MeCP2 also binds massively to chromatin, thus acting as a chromatinCiencias de la Salud (IACS), San
te BIFI - University of Zaragoza,
poy).
Spainarchitecture remodeling factor by replacing histone H1 as a nucleoso-
mal linker [2–4]. These different modes of interaction with DNA, as
well as its ability to interact with many other different biological
partners (RNA, structural and transcriptional proteins, nucleosomal ele-
ments) and its multifaceted cellular role regulated by post-translational
modifications are made possible by its modular, dynamic and adaptive
structure [5,6]. MeCP2 is an important hub within gene transcription
regulation networks. However, recent evidences suggest a primary
role consisting of recruiting co-repressor complexes to methylated
sites in the genome, resulting in dampened gene expression [7].
MeCP2 deregulation leads to disease [8–10]. MeCP2 pointmutations
or deletions causing activity loss or deficiency are associated with Rett
syndrome (RTT). Although a rare disease (1:10000 births), RTT is the
main cause of mental retardation in females, characterized by a clini-
cally varied expression and sharing features with other neurological
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expression of MeCP2 and leads to MeCP2 duplication syndrome (MDS),
another much rarer disorder affecting males and sharing some pheno-
typic features with RTT (e.g., severe intellectual disability and impaired
motor function).
MeCP2 is an intrinsically disordered protein (IDP). Most of its poly-
peptide chain (~ 60%) lacks well-defined secondary/tertiary structure.
MeCP2 share some features with other IDPs, such as a high content in
charged and polar residues (Table S1). The presence of flexible regions
facilitates structural rearrangements necessary for allosteric regulation
(in a broad sense, allosteric control consists on the modulation of the
protein conformational landscape through ligand binding) and for ex-
posing different motifs to interact with different partners. Interactions
in IDPs are often characterized by a moderate-to-low binding affinity
and a transient nature, because of the energetic penalty stemming
from the conformational change coupled to the binding.
MeCP2 is organized into six domains: N-terminal domain
(NTD), methyl binding domain (MBD), intervening domain (ID),
transcriptional repression domain (TRD), C-terminal domain α (CTDα),
and C-terminal domain β (CTDβ) (Supplementary Fig. S1) [2,11]. The
most important domains are MBD, initially associated with methylated
CpG (mCpG)DNAbinding, and TRD, associatedwith transcription repres-
sion activity [12,13]. Most of the mutations associated with RTT are lo-
cated in these two domains [14]. However, it has been shown that other
domains (ID, CTDα and CTDβ) are also directly or indirectly involved in
methyl-independent DNA interaction [11,15].
MBD is the best characterized domain in MeCP2. MBD structure ba-
sically consists of a wedge-shaped structured core containing a 3-
stranded anti-parallel β-sheet with an α-helix on the C-terminal side,
with two unstructured regionsflanking this core [16,17].MBD is consid-
ered to be directly involved in maintaining the global organization of
the protein through interactions with other domains through inter-
domain coupling [4]. Mutations in this domain would have an impact
on the local and the global stability in MeCP2 [2,18].
There are many (completely or partially) unexplained issues related
to MeCP2 function, such as: 1) the small difference in the binding affin-
ities determined in vitro for methylated and unmethylated DNA, which
is far from being biologically significant to explain its preferential distri-
bution tracking the density of 5-methyl-cytosines heterochromatin foci
[5,19,20]; 2) the mechanisms by which MeCP2 is able to both activate
and deactivate the transcription of hundreds of genes, depending on
the context (e.g., decreasing transcriptional noise and adapting gene ex-
pression pattern to different physiological or environmentally-induced
conditions) [21,22]; 3) the inter-domain interactions and dependencies
giving rise to cooperative phenomena regarding structural and func-
tional features inMeCP2; 4) the role of the different DNA bindingmotifs
along its sequence; are they functionally independent allowing the in-
teractionwith several DNA stretches simultaneously?; 5) the possibility
for MeCP2 to bind to dsDNA in a cooperative fashion, where some do-
mains would play a structural/functional role [4,23]; 6) the ability of
MeCP2 for simultaneously showing methylation-dependent specific
binding to certain target gene promoter locations and genome-wide
methylation-independent unspecific binding to heterochromatin
[24–26]; 7) the ability to recognize not only methyl-cytosine, but
also other methylated nucleotides with high affinity [27]; 8) the
large number of similar symptoms associated with RTT and MDS,
two disorders caused by the down- and upregulation of MeCP2, re-
spectively; and 9) the presence of two MeCP2 isoforms (E1 and E2)
differing in just a few N-terminal residues and showing different ex-
pression patterns and non-redundant functions, being E2 the most
widely studied and characterized isoform, but the onewith lower ex-
pression level [28].
Besides recent, spectacular advances in cellular and gene therapy
(e.g., gene edition using CRISPR techniques), drug discovery and devel-
opment remains as a useful strategy for efficient therapeutic tools. Al-
though many efforts have been devoted to improve palliative care or59to restore intracellular signaling and metabolic routes altered because
of abnormal MeCP2 activity, a possible strategy for RTT and MDS drug
development consist in the search for small molecules able to bind to
MeCP2 stabilizing and rescuing defective mutants associated with RTT,
or able to bind to MeCP2 inhibiting its activity for MDS treatment.
From a practical point of view, full-lengthMeCP2 is a protein presenting
considerable difficulties because it is prone to degradation and precipi-
tation. Thus, depending on the goal (i.e., improving or rescuing DNA
binding or gene transcription), different protein constructs or variants
can be specifically designed for laboratory work (e.g., biophysical struc-
tural and functional studies, cell-based assays, high-throughput molec-
ular screening and drug discovery). In a previous biophysical study of
three MeCP2 variants (MBD, and NTD-MBD, and NTD-MBD-ID), we
established that the isolated MBD might not be the appropriate con-
struct to study and assay its DNA binding features, because the presence
of NTD and ID increased considerably the DNA binding affinity and the
structural stability, besides adding a second, functionally independent
and relevant DNA binding site [29].
Here we report a biophysical study of the structural stability and the
DNA interaction of the remaining MeCP2 variants: NTD-MBD-ID-TRD,
NTD-MBD-ID-TRD-CTDα, and NTD-MBD-ID-TRD-CTDα-CTDβ (full-
length MeCP2). The purpose was to find out if distant disordered do-
mains would affect MBD structural and functional features, if a longer
variant for MeCP2 would be more appropriate for biophysical studies
and drug discovery programs, and if the presence of additional AT-
hooks (in TRD and CTDα) would result in additional functionally inde-
pendent DNA binding sites.
2. Materials & methods
2.1. Plasmid construction
MeCP2 (isoform E2) variants were inserted in a pET30b plasmid for
protein expression. The different protein variants were obtained by
inserting appropriate stop codons: NTD-MBD-ID-TRD, NTD-MBD-ID-
TRD-CTDα, and NTD-MBD-ID- TRD-CTDα-CTDβ (Fig. S1). The protein
sequences contained anN-terminal polyhistidine-tagwhichwas always
removed after purification through an inserted PreScission Protease rec-
ognition cleavage site. All sequences were checked by sequencing anal-
ysis. The protein variants were checked and corroborated by Sanger
sequencing using a BigDye Terminator v3.1 Cycle Sequencing Kit (Life
Technologies, Carlsbad, CA, USA) in an Applied Biosystems 3730/DNA
Analyzer (Thermo Fisher Scientific, Waltham, MA, USA). The data
were analyzed with BioEdit Sequence Alignment Editor [30].
2.2. Protein expression and purification
All protein variants (NTD-MBD-ID-TRD,NTD-MBD-ID-TRD-CTDα, and
NTD-MBD-ID-TRD-CTDα-CTDβ/full-length MeCP2) were expressed and
purified following the same procedure. Plasmids were transformed into
BL21 (DE3) Star E. coli strain. Bacteria cultures were grown in 150 mL of
LB/kanamycin (50 μg/mL)media at 37 °C overnight. Then, 4 L of LB/kana-
mycin (25 μg/mL) were inoculated (1:100 dilution) and incubated under
the same conditions until reaching an OD (at a wavelength of 600 nm) of
0.6. Protein expression was induced with 1 mM isopropyl 1-thio-β-D-
galactopyranoside (IPTG) at 18 °C overnight. Cells were ruptured by
sonication in ice and benzonase (Merck-Millipore, Madrid, Spain) was
added (20 U/mL) to remove nucleic acids. Proteins were purified using
immobilized metal ion affinity chromatography (IMAC) in a HiTrap
TALON column (GE-Healthcare Life Sciences, Barcelona, Spain) with two
washing steps: buffer sodium phosphate 50 mM, pH 7, NaCl 300 mM,
and in buffer sodium phosphate 50 mM, pH 7, NaCl 800 mM (to remove
potential DNA contamination from the protein), before an imidazole
10–150 mM elution gradient. Purity was checked by SDS-PAGE.
Removal of the histidine-tag was performed by GST-tagged
PreScission Protease processing in cleavage buffer (50 mM Tris-HCl,
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was checked by SDS-PAGE. Finally, proteins were further purified using
a combination of two affinity chromatographic steps to remove the
histidine-tag (HiTrap TALON column, from GE-Healthcare Life Sciences,
Barcelona, Spain) and the GST-tagged PreScission Protease (GST TALON
column, from GE-Healthcare Life Sciences, Barcelona, Spain). Purity and
homogeneity were checked by SDS-PAGE and size-exclusion chroma-
tography. The proteins were stored in buffer Tris 50 mM pH 7.0 at
−80 °C. The identity of all proteins was checked by mass spectrometry
(4800plus MALDI-TOF/MS, from Applied Biosystems - Thermo Fisher
Scientific, Waltham, MA, USA). Potential DNA contamination was al-
ways checked determining the ratio of UV absorption at 260 nm vs ab-
sorption at 280 nm. An extinction coefficient of 11,460 M−1 cm−1 at
280 nm was employed for all variants (a single tryptophan is located
in MBD), except for the full-length protein (13,075 M−1 cm−1).
Stability and binding assays were performed at different pH and
buffer conditions (Tris 50 mM pH 7–9, NaCl 0–150 mM; Pipes 50 mM,
pH7; Phosphate 50mM, pH7).Whenneeded, buffer exchangewas per-
formed using a 3 or 10 kDa-pore size ultrafiltration device (Amicon cen-
trifugal filter, Merck-Millipore, Madrid, Spain) at 4000 rpm and 4 °C.
2.3. Double-stranded DNA
HPLC-purifiedmethylated and unmethylated 45-bp single-stranded
DNA (ssDNA) oligomers corresponding to the promoter IV of themouse
brain-derived neurotrophic factor (BDNF) gene [15,18] were obtained
from Integrated DNA Technologies. Two complementary pairs of DNA
were used for DNA binding assays: forward unmethylated: 5′- GCCA
TGCCCTGGAACGGAACTCTCCTAATAAAAG-ATGTATCATTT-3′; reverse
unmethylated: 5′- AAATGATACATCTTTTATTAGGAGAGTTCCGTTCC-
AGGGCATGGC-3′; forward mCpG: 5′- GCCATGCCCTGGAA(5-Me)CGGA
ACTCTCCTAATAAA-AGATGTATCATTT-3′; reverse mCpG: 5′- AAATGA
TACATCTTTTATTAGGAGAGTTC(5-Me)CGTT-CCAGGGCATGGC-3′.
The DNA fragments were purchased as ssDNA oligonucleotides and
they were subsequently annealed to obtain 45-bp double-stranded
DNA (dsDNA) for the interaction experiments. Briefly, they were dis-
solved to obtain a 0.5 mM ssDNA solution for each oligonucleotide;
then, they were mixed at an equimolar ratio and were annealed using
a Stratagene Mx3005P qPCR real-time thermal cycler (Agilent Technol-
ogies, Santa Clara, CA, USA). The thermal annealing profile consisted of
four steps: 1) equilibration at 25 °C for 30 s; 2) heating ramp up to
99 °C; 3) equilibration at 99 °C for 60 s; and 4) 3-h cooling process
down to 25 °C at a rate of 1 °C/180 s.
2.4. Circular dichroism
Far-UV circular dichroism spectra were recorded in a Chirascan (Ap-
plied Photophysics, Leatherhead, UK) using a 0.1 cm path-length quartz
cuvette (Hellma Analytics, Müllheim, Germany). The temperature was
controlled by a Peltier unit and monitored using a temperature probe.
Circular dichroism (CD) spectrawere recorded in a Chirascan spectro-
polarimeter (Applied Photophysics, Leatherhead, UK) at 25 °C. Far-UV
spectrum was recorded at wavelengths between 200 and 260 nm in a
0.1 cm path-length cuvette (Hellma Analytics, Müllheim, Germany). Pro-
tein concentration was 10–20 μM. The temperature was controlled by a
Peltier unit and monitored using a temperature probe. Molar residue el-
lipticity was calculated considering the concentration of protein and the
number of residues for each variant.
2.5. Fluorescence spectroscopy
Thermal unfolding studies were performed in a Cary Eclipse fluores-
cence spectrophotometer (Varian – Agilent, Santa Clara, CA, USA) using
a 1 cm path-length quartz cuvette (Hellma Analytics, Müllheim,
Germany). The temperature was controlled by a Peltier unit and moni-
tored using a temperature probe. Fluorescence emission spectra were60recorded from 300 to 400 nm using an excitation wavelength of
290 nmand a bandwidth of 5 nm. Protein concentrationwas set at 5 μM.
Thermal stability assays were performed at a heating rate of 1 °C/min
and at the emission wavelength for maximal spectral change (330 nm).
Thermal unfolding of the protein was reversible and the experiments
were analyzed considering a two-state unfolding model:
F ¼
AN þ BNTð Þ þ AU þ BUTð Þ exp −ΔG Tð ÞRT
 
1þ exp −ΔG Tð Þ
RT
 
ΔG Tð Þ ¼ ΔH Tmð Þ 1− TTm
 
þ ΔCP T−Tm−T ln TTm
 
ð1Þ
where F is the fluorescence signal, T is the absolute temperature, Tm is
the midtransition temperature, ΔH(Tm) is the unfolding enthalpy, ΔCP
is the unfolding heat capacity, and ΔG is the stabilization Gibbs energy.
The adjustable parameters AN, BN, AU, and BU define the pre- (native)
and post-transition (unfolded) regions in the temperature unfolding
trace. The stabilizing effect upon dsDNA interaction was assessed by
performing thermal denaturations of the different proteins (at 5 μM)
in the presence of methylated and unmethylated DNA (at 10 μM) under
the same conditions.
2.6. Isothermal titration calorimetry (ITC)
The interaction between the different proteins and dsDNAwas char-
acterized using an Auto-iTC200 microcalorimeter (MicroCal, Malvern-
Panalytical, UK). Protein in the calorimetric cell at 3–5 μM was titrated
with dsDNA at 50 μM. All solutions were degassed at 15 °C for 2 min be-
fore each assay. A sequence of 2 μL-injections of titrant solution every
150 s was programmed and the stirring speed was set to 750 rpm. The
association constant, KB,obs, and the enthalpy of binding, ΔHB,obs, were
estimated through non-linear regression of the experimental data
employing a single ligand binding site model (1:1 protein:dsDNA stoi-
chiometry) for ID interacting with dsDNA, or a two ligand binding sites
model (1:2 protein:dsDNA stoichiometry) for NTD-MBD-ID and longer
variants interacting with dsDNA, implemented in Origin (OriginLab,
Northampton, MA). A detailed description of those models applied in
ITC can be found elsewhere [31,32]. The dissociation constant Kd was
calculated as the inverse of KB,obs, and the binding Gibbs energy and en-
tropy were calculated applying standard well-known relationships:
ΔG = −RT lnKB, ΔG= ΔH - TΔS.
The association constant KB,obs is not affected by the buffer ionization
as long as the pKa of the buffer is close to the experimental pH. However,
the observed binding enthalpy (and, therefore, the entropic contribu-
tion) will contain an additional contribution from buffer ionization.
Those extrinsic contributions from the buffer can be removed. The
buffer-independent binding enthalpy, ΔH, was determined according
to [33–35]:
ΔHB,obs ¼ ΔH þ ΔnHΔHbuffer ð2Þ
where ΔnH is the net number of protons exchanged between the
protein-dsDNA complex and the bulk solution upon dsDNA binding,
andΔHbuffer is the ionization enthalpy of the buffer. Titrationswere per-
formed in buffers with different ionization enthalpies (Tris, 11.35 kcal/
mol; Pipes, 2.67 kcal/mol; and phosphate, 0.86 kcal/mol) [36] in order
to estimate the buffer-independent thermodynamic parameters (ΔH
and ΔnH) from linear regression using eq. 2. Knowing the binding
Gibbs energy and the buffer-independent binding enthalpy, the
buffer-independent binding entropy can be readily calculated. The
parameter ΔnH may be non-zero when ligand binding results in
changes in the proton dissociation constant of certain ionizable res-
idues (in the protein or the ligand) as a consequence of changes in
their microenvironment upon complex formation. Interestingly,
Fig. 2. Unfolding temperature of all MeCP2 protein variants in the absence of dsDNA (black
bars), and the presence unmethylated CpG-dsDNA (red bars) and methylated mCpG-
dsDNA (green bars), obtained from thermal denaturations followed by intrinsic tryptophan
fluorescence.
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change in binding affinity as a result of a change in pH:





3.1. Distant domains in MeCP2 exert a considerable stabilizing effect
on MBD
The poor circular dichroism signal related to the low content in sec-
ondary structure of the protein variants (Fig. S2) and its small change
during the thermal denaturation process within the 10–90 °C tempera-
ture range favored the use of fluorescence spectroscopy in the thermal
unfolding assays. The single tryptophan residue in MeCP2, located in
the MBD, allowed monitoring the thermal denaturation of the different
variants by focusing specifically on the intrinsic stability of this domain.
Importantly, the lack of tryptophan residues in all other domains was
instrumental for directly observing the stabilizing effect of the other do-
mains on the MBD. There is an additional tyrosine in full length MeCP2,
but its contribution to the overall fluorescence intensity is expected to
be small. Nomajor differenceswere observed in the shape of the spectra
of the three variants; all of them showed a maximum around 330 nm,
which underwent a reduction in intensity and a red-shift to 335 nm
when the temperature was increased. The fluorescence emission inten-
sity was strongly affected by the presence of distant domains (Fig. S2),
indicating those domains exert an influence on the tryptophan environ-
ment in MBD through inter-domain long-distance interactions. Major
differences between the variants were the emission intensity tempera-
ture range at which the intensity decrease and the red-shift occur, and
this is what the unfolding fluorescence traces captured (Fig. 1).
The three variants (NTD-MBD-ID-TRD, NTD-MBD-ID-TRD-CTDα,
and NTD-MBD-ID-TRD-CTDα-CTDβ/full length) showed aminor stabil-
ity dependency on the pH, much smaller for the full-length protein
(Fig. S1, and Table S2). This indicates the potential influence of ionizable
amino acids in this pH range is negligible, and the selection of pH 7 for
further experiments will not condition the reliability of the results.
The unfolding temperature, Tm, showed an increasing trend with the
length of the protein variant at pH 7, although that stabilizing effect
already reaches the maximal extent when NTD and ID are present
(Fig. 2 and Table S2). In addition, physiological high ionic strength
(NaCl 150 mM) increased the stability for all variants at pH 7 (Figs. 1
and S2-S3, and Table S2), with regard to low ionic strength, which indi-
cates that the unfolding process is coupled to theuptake of ions from the
bulk solution, as previously observedwith other smallerMeCP2 variants
[29]. The experiments at high ionic strength also confirm the increasing
trend for Tm with the length of the protein variant.Fig. 1. Fluorescence thermal denaturations for the MeCP2 variants (a) NTD-MBD-ID-TRD, (b)
strength. The influence of the presence of dsDNA on the thermal stability was assessed for th
methylated mCpG-dsDNA, green squares). All unfolding traces could be fitted employing a tw
one out two experimental data points are shown. (For interpretation of the references to colou
61The presence of dsDNA stabilized all protein variants (Figs. 1 and 2,
and Table S3). Longer protein variants underwent a larger stabilization
effect upon dsDNA interaction. Importantly, the stabilization effect
was considerably larger for methylated mCpG-dsDNA, compared to
unmethylated CpG-dsDNA,whichwould point to a higher binding affin-
ity for methylated dsDNA (Figs. 1 and 2, and Table S3). The difference in
the stabilization effect exerted by both dsDNA types was conserved for
all variants (Fig. 2), pointing to an affinity difference conserved for all
protein variants. At high ionic strength the stabilizing effect of dsDNA
was smaller (Fig. S4, and Table S4), which indicates that the dsDNA
binding affinity decreases with the ionic strength, and that the dsDNA
binding must be coupled to the release of ions from the complex toNTD-MBD-ID-TRD-CTDα, and (c) NTD-MBD-ID-TRD-CTDα-CTDβ, at pH 7 and low ionic
e three variants (dsDNA-free, black squares; unmethylated CpG-dsDNA, red squares; and
o-state unfolding model (continuous lines) according to eq. 1. For clarity purposes, only
r in this figure legend, the reader is referred to the web version of this article.)
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larger for methylated mCpG-dsDNA, compared to unmethylated
CpG-dsDNA. Somewhat different results, but showing a similar sta-
bilization trend, have been reported before under different condi-
tions [15].
3.2. Distant domains inMeCP2 exert aminor influence on dsDNA binding to
MBD and ID
The ability of ID to interact with DNAwas reported before [4]. In fact,
somemutations in ID hinderMeCP2 chromatin association [4,38]. It was
previously observed that the presence of ID (variant NTD-MBD-ID) has
important consequences regarding the dsDNA binding capabilities of
the MBD: 1) the ID provides another dsDNA binding site that is func-
tionally independent from that located in MBD (i.e., the variant NTD-
MBD-ID is able to interact with two dsDNA fragments); and 2) the ID
dramatically increases the dsDNA binding affinity of the MBD [29].
However, a precise binding affinity determination for ID was lacking.
Therefore, we first assessed the ability of isolated ID to interact with
dsDNA. ID interacted with submicromolar binding affinity with both
methylated and unmethylated dsDNA (Fig. 3 and Table S5), therefore,
confirming its ability to interact with dsDNA and its inability to discrimi-
nate between both dsDNA types. Surprisingly, although ID is a completely
disordered domain, the dsDNA interaction is characterized by an unfavor-
able binding enthalpy and a largely favorable binding entropy, likely asso-
ciated with a large desolvation of binding interfaces.
Then, we proceeded to assess the dsDNA binding characteristics of
MeCP2 variants. The dsDNA binding parameters for NTD-MBD-ID-TRD
and NTD-MBD-ID-TRD-CTDα variants are quite similar, and essentially
identical to those observed for NTD-MBD-ID (Fig. 4 and Table S5), ex-
cept for a less exothermic binding of dsDNA to the MBD high-affinity
binding site. Therefore, we proceeded to evaluate the dsDNA binding
for the NTD-MBD-ID-TRD-CTDα-CTDβ variant (full-length MeCP2),
which is the most physiologically relevant protein variant (except in
the case of clinically relevant deletion mutations associated with RTT).
Except a slightly higher affinity for the second low-affinity binding site
and a more endothermic binding for the low-affinity binding site, the
interaction of the three variants (NTD-MBD-ID-TRD and NTD-MBD-ID-
TRD-CTDα, and NTD-MBD-ID-TRD-CTDα-CTDβ) with dsDNAwas simi-
lar (Fig. 5, and Table S5). The differences in the binding affinity betweenFig. 3. Interaction of the IDwith dsDNA by isothermal titration calorimetry (ITC) at pH 7. The in
at pH 7. Upper plots show the thermogram (raw thermal power as a function of time) and the
molar ratio). Non-linear least-squares analysis using a single binding site model allowed estima
for estimating the buffer-independent binding enthalpy: CpG-dsDNA (open squares) and mCp
size of the symbols.
62methylated and unmethylated dsDNA (i.e., the ability to discriminate
between both dsDNA forms) in both binding sites for these three vari-
ants seem to be similar to those observed for NTD-MBD-ID.
4. Discussion
The structural and functional role of disordered regions in proteins is
controversial. These regions are characterized by a biased amino acid
composition, where residues exhibiting considerable propensity to be
exposed to the solvent predominate (polar and charged amino acids)
[39]. However, they may exert a steric hindrance effect, or establish at-
tractive or repulsive electrostatic interactions, or make key contacts
with other structured regions and affect the global stability and the dy-
namics of the protein, as well as modulate the interaction with binding
partners. Therefore, the impact of disordered regions on the global sta-
bility may be based on specific or unspecific effects. Specific effects may
derive from long-lived or transient interactions between residues from
disordered and structured regions, while unspecific effects may be due
to reciprocal constrained flexibility/mobility of the polypeptide chain
because of steric or electrostatic hindrance. Long-range electrostatic
and dipolar interactions are extremely important in IDPs, especially at
low ionic strength, because of the large fraction of charged and polar
residues. Therefore, it may be possible that, even lacking well-defined
structure, disordered regions can contribute to the overall stability of
the protein [40]. In the case of MeCP2, we have recently provided evi-
dence for that phenomenon: 1) NTD and ID, two completely disordered
domainsflanking theMBD, increase significantly the thermal stability of
the MBD [29]; and 2) the two MeCP2 isoforms E1 and E2, which only
differ in a few N-terminal aminoacids in the completely disordered do-
main NTD, show different thermal stability [28].
As indicated above, the purpose of this work was to determine: 1) if
distant disordered domains in MeCP2 would affect MBD structural and
functional features, 2) if a longer variant for MeCP2 would be more ap-
propriate or compulsory for structural/functional assays, and 3) if the
presence of additional AT-hooks (in TRD and CTDα) would result in ad-
ditional functionally independent DNA binding sites.
The single tryptophan residue located in theMBD facilitated the task
of observing local stability changes in theMBD induced by other distant
domains. The presence of additional partially disordered domains en-
hanced the stability of MBD, although the increase in stability wasteraction of unmethylated CpG-dsDNA (a) andmethylatedmCpG-dsDNA (b) was assessed
lower plots show the binding isotherm (ligand-normalized heat effects as a function of the
ting the observed binding affinity and enthalpy (continuous lines). (c) Eq. 2 was employed
G-dsDNA (closed squares). Errors for the observed binding enthalpies are smaller than the
Fig. 4. Interaction of the NTD-MBD-ID-TRD (a) and NTD-MBD-ID-TRD-CTDα (b) with methylated mCpG-dsDNA by isothermal titration calorimetry (ITC) at pH 7. Upper plots show the
thermogram (raw thermal power as a function of time) and the lower plots show the binding isotherm (ligand-normalized heat effects as a function of the molar ratio). Non-linear least-
squares analysis using a two binding sites model allowed estimating the observed binding affinity and enthalpy (continuous lines). Eq. 2 was employed for estimating the buffer-
independent binding enthalpy for the MBD high-affinity binding site (squares) and the ID low-affinity binding site (triangles) for NTD-MBD-ID-TRD (c) and NTD-MBD-ID-TRD-CTDα
(d). Errors for the observed binding enthalpies are smaller than the size of the symbols.
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perature could be observed when increasing the length of the polypep-
tide chain (Fig. 2 and Table S2). Albeit the unfolding temperature may
often be a quick, convenient index to judge or rank structural stability,
it is an index reporting stability at high temperature, and very frequently
a protein stability ranking based on the unfolding temperature does not
correlate with a protein stability ranking based on the stabilization en-
ergy at room or physiological temperature. Thus, the stabilization GibbsFig. 5. Interaction of the NTD-MBD-ID-TRD-CTDα-CTDβ (full-length MeCP2) with unmethylat
(ITC) at pH 7. Upper plots show the thermogram (raw thermal power as a function of time
function of the molar ratio). Non-linear least-squares analysis using a two binding sites mo
(c) Eq. 2 was employed for estimating the buffer-independent binding enthalpy for the MBD
dsDNA (open symbols) and mCpG-dsDNA (closed symbols). Errors for the observed binding e
63energy at 20 °C for each variant was calculated employing Eq. (1)
(Fig. 6). The calculation of the stabilization Gibbs energy at 20 °C involves
a substantial extrapolation, in some cases over a range of more than
50 °C, and caution must be taken when performing these calculations.
A similar trend to that of Tm can be observed for the stabilization Gibbs
energy: the longer the variant, the larger the stability Gibbs energy. In
addition, the binding ofmethylated and unmethylated dsDNA further in-
creases the protein stability; in all protein variants, the stabilization effected CpG-dsDNA (a) and unmethylated CpG-dsDNA (b) by isothermal titration calorimetry
) and the lower plots show the binding isotherm (ligand-normalized heat effects as a
del allowed estimating the observed binding affinity and enthalpy (continuous lines).
high-affinity binding site (squares) and the ID low-affinity binding site (triangles) CpG-
nthalpies are smaller than the size of the symbols.
Fig. 6. Stability Gibbs energy at 20 °C of allMeCP2protein variants in the absence of dsDNA
(black bars), and the presence unmethylated CpG-dsDNA (red bars) and methylated
mCpG-dsDNA (green bars). The stability Gibbs energy was estimated considering a two-
state unfolding model (eq. 1).
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dsDNA. The overall stabilization Gibbs energy, ΔG, in the presence of
an interacting ligand is equal to the intrinsic stabilization Gibbs energy,
ΔG0, plus the excess average binding Gibbs energy, <ΔGB>, which is
the contribution to the stability from ligand binding. Focusing on full-
length MeCP2, the intrinsic stabilization Gibbs energy is 2.7 kcal/mol,
and the binding of unmethylated CpG-dsDNA and methylated mCpG-
dsDNA increases the stabilization energy to 6.9 kcal/mol and 11.3 kcal/
mol, respectively (Fig. 6). Then, the binding of dsDNA contributes 60%
and 75% of the global stabilization energy of the complex (at the 1:2 pro-
tein:dsDNA concentration ratio employed in the thermal unfolding ex-
periments, protein 5 μM and DNA 10 μM). From those data, it could be
reasonable to hypothesize a higher binding affinity for methylated
mCpG-dsDNA compared to unmethylated CpG-dsDNA.
ITC is currently considered the gold-standard for determining bind-
ing affinities in biomolecular interactions. This technique allows the si-
multaneous determination of the binding affinity (association constant,
dissociation constant, or Gibbs energy of binding) and the binding en-
thalpy, as well as the stoichiometry. Very importantly, the binding affin-
ity will not be affected by ionization properties of the buffer, as long as
the experimental pH is close to the pKa of the buffer. On the contrary,
the binding enthalpy (and, therefore, the binding entropy also) might
contain considerable contributions from the ionization enthalpy and en-
tropy of the buffer. Fortunately, there is a straightforward procedure that
allows removing the buffer contributions, thus obtaining the buffer-
independent binding parameters, and at the same time estimating the
net number of protons that are exchanged between complex and bulk
solution upon complex formation. This quantity may be explored in64detail in order to get insight into the ionizable functional groups involved
in the binding process [41,42], and, from the practical point of view, it
provides information, although limited, on the dependency of the bind-
ing affinity with pH (eq. 3). In addition, ITC is very well suited for study-
ing biological interactionswithmore than one binding site, as it happens
with NTD-MBD-ID and longer MeCP2 variants, since the interplay be-
tween binding affinity and enthalpy makes easy to observe different
binding process occurring at different locations on a macromolecule
through a multiphasic binding isotherm.
Overall, except some differences in the binding enthalpies, the three
variants considered in this work do not behave differently compared to
NTD-MBD-ID regarding dsDNAbinding affinity, difference in binding af-
finity between the high- and low-affinity sites, ability to discriminate
between unmethylated and methylated dsDNA in both sites, and bind-
ing stoichiometry. Focusing on the full-length protein, the interaction
with methylated mCpG-dsDNA shows a more favorable enthalpy in
the high-affinity site and a less unfavorable enthalpy in the low-
affinity site. For both dsDNAs, the binding to the high-affinity site is
enthalpically driven and the binding to the low-affinity site is entropi-
cally driven. Still, the entropic contribution to the binding of both sites
is favorable in both cases. In addition, the dsDNA binding to the high-
affinity site is coupled to a net deprotonation (ΔnH < 0) in the complex,
while the dsDNA binding to the low-affinity site is coupled to a net pro-
tonation (ΔnH > 0).
There are several intriguing facts derived from the experimental re-
sults reported here. First, the large differences in stabilization effects in-
duced by unmethylated CpG-dsDNA and methylated mCpG-dsDNA (in
terms of increases in Tm or ΔG(20 °C)) do not correlate with the small
differences in binding affinities estimated from ITC. This was previously
observed, and it is under further scrutiny in our group. One explanation
could be that in experimental assayswhere the steady-state effect of the
interaction between protein and ligand is observed after long incuba-
tion (e.g., steady-state spectroscopy, chemical and thermal denatur-
ations, inhibition assays) there is sufficient time for the complex to
achieve the optimal binding configuration, whereas in experimental as-
says where the transient effect of the interaction in the first minutes
after instantaneous mixing (e.g., ITC) there might not be sufficient
time to achieve optimal final binding configuration and lower binding
affinitiesmay be estimated. In this sense, differences in binding affinities
as determined by different techniques or a slow adaptation of the ligand
within the binding site to achieve an optimal binding affinity have been
observed before for biological systems [43–45]. However, steady-state
fluorescence spectroscopy experiments provided binding affinities for
methylated and unmethylated dsDNA similar to those determined by
ITC (Fig. S5). MeCP2 was initially identified as a methyl-specific
dsDNA binder, as confirmed by cellular and in vivo assays. Would the
absence of discrimination between unmethylated CpG-dsDNA and
methylated mCpG-dsDNA in both binding sites in in vitro assays be an
indication for the need of an additional factor (a protein cofactor?)
allowing such effective methyl-dependent discrimination? Maybe this
is something requiring further attention.
Second, the presence of additional domains with potential dsDNA
binding motifs (AT-hooks in TRD and CTDα, besides the binding sites
in MBD and ID) did not increase the dsDNA binding stoichiometry in
MeCP2. Themaximumnumber of dsDNAmoleculesMeCP2 is able to in-
teractwith simultaneously is two (1:2MeCP2:dsDNA). Other stoichiom-
etries or binding configurations (e.g., 2:1 MeCP2:dsDNA, or 1:1 MeCP2:
dsDNA) are not compatible with the results presented here. This maxi-
mal stoichiometry already arises in the NTD-MBD-ID variant. Therefore,
no additional, functionally independent DNA binding sites could be ob-
served when TRD and both CTDs were present. Still, this may be suffi-
cient for its genome-wide chromatin remodeling/compacting function.
From the results presented here, there is no possibility to conclude un-
ambiguously where the main DNA-attachment spot for the second,
low-affinity binding site is located in the three variants. That site could
be located in ID, TRD or CTDα. There is a need for structural data
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independent binding site has already been identified and characterized
in ID. It would be possible that those additional dsDNA binding motifs
from TRD and CTDα, different from the main one located in the MBD
and the secondary one in ID, would wrap around the same dsDNA frag-
ments, thus cooperating to achieve a high binding affinity and a high ki-
netic barrier towards dissociation.
And third, the 45-bp dsDNA employed in the experiments would be
long enough to accommodate several MeCP2 molecules bound, at least
for the smaller variants (e.g., MBD or NTD-MBD-ID). However, accord-
ing to the stoichiometry observed in the ITC experiments (this work
and [29]) and ultracentrifugation experiments [29], no simultaneous
binding of more than one MeCP2 molecule on the dsDNA molecule
could be observed, thus, ruling out cooperativity for MeCP2 binding to
dsDNA in vitro.
5. Conclusions
MeCP2 is a potential pharmacological protein target associated with
RTT (caused by lack of MeCP2 activity) and MDS (caused by excess of
MeCP2 activity), two neurological disorders with similar phenotypic
features. MeCP2 is mainly involved in neuronal development andmatu-
ration, and synaptic plasticity. MeCP2 is a partially disordered, multiple-
domain protein exhibiting multiple functions: activation/repression of
transcription at specific promoter locations, genome-wide chromatin
remodeling and nucleosomal compaction, and pre-mRNA maturation
and splicing, among the most important ones. The structural properties
(modularity and plasticity) in MeCP2 are responsible for its complex
conformational/functional landscape and its many biological functions.
No drugs acting specifically on MeCP2 have been developed so far.
Therefore, high-throughput screening programs for identifying bioactive
molecules capable of modulating MeCP2 function would be desirable.
However, heterologous expression of MeCP2 for in vitro assays exhibits
some problems undermining its tractability: low expression yield, high
propensity to degradation, and high propensity to precipitation. Although
some appropriate MeCP2 constructs or variants can be envisaged consid-
ering MeCP2 modularity and the inferred functions for each domain, as
well as the purpose of the assay (e.g., molecular screening, in vitro func-
tion, cell-based assay…), the assessment of the stability and the functional
features of the different variantswould be necessary. In thisworkwehave
evaluated the structural stability (stability against thermal denaturation,
the stabilization effect of unmethylated and methylated dsDNA), and the
ability to interact with unmethylated andmethylated dsDNA (determina-
tion of binding affinity and enthalpy) of different MeCP2 variants with
variable length. In particular, theNTD-MBD-ID variantwould be appropri-
ate for identifying small molecules able to recover or inhibit MeCP2 inter-
action with dsDNA (intended for therapeutic treatment of RTT or MDS,
respectively), since it has sufficient structural stability and its functional
behavior related to dsDNA interaction is similar to other longer variants,
including full length MeCP2. Nevertheless, if the compound screening is
aimed at identifying small molecules modulating MeCP2 protein-protein
interactions, then, longer variants including TRD and/or CTDs would be
required.
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